Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status. - Brose MS; Keam B; Krajewska J; Hoff AO; Vaisman F; Lin CC; Hitre E; Bowles DW; Robinson B; Sherman SI; Ngamphaiboon N; Guo X; et al. (Frontiers in oncology, 2026)